Skip to main content
. 2019 Sep 23;13:3357–3367. doi: 10.2147/DDDT.S215337

Table 2.

Effects of loratadine (0.5–50 mg/kg p.o.) on the length, mass, composition, and mineralization of the femur in young male rats

Parameter/Group C L0.5 L5 L50
Bone length (mm) 33.84 (33.02–34.92) 33.81 (32.81–34.70) 33.30 (29.72–34.33) 33.26 (32.30–33.67)**
Bone mass (g) 0.678 (0.622–0.718) 0.692 (0.635–0.739) 0.677 (0.593–0.722) 0.688 (0.580–0.729)
Bone mineral mass (g) 0.258 (0.244–0.276) 0.257 (0.245–0.289) 0.249 (0.211–0.273) 0.259 (0.206–0.286)
Mass of bone mineral /bone mass ratio 0.387 (0.359–0.402) 0.379 (0.361–0.400) 0.368 (0.355–0.396) 0.377 (0.355–0.414)
Mass of bone water /bone mass ratio 0.373 (0.341–0.407) 0.378 (0.355–0.396) 0.385 (0.362–0.399) 0.381 (0.333–0.404)
Mass of bone organic substances/bone mass ratio 0.241 (0.234–0.257) 0.244 (0.240–0.254) 0.246 (0.236–0.253) 0.241 (0.239–0.253)
Calcium content (g/g of bone mineral) 0.379 (0.352–0.391) 0.377 (0.358–0.404) 0.375 (0.352–0.387) 0.382 (0.358–0.404)
Phosphorus content (g/g of bone mineral) 0.163 (0.156–0.176) 0.160 (0.141–0.180) 0.161 (0.157–0.182) 0.162 (0.154–0.184)
Molar Ca/P ratio 1.79 (1.59–1.91) 1.86 (1.60–2.04) 1.80 (1.60–1.88) 1.82 (1.61–1.97)

Notes: Results are presented as median (min–max); n=8–10. Loratadine at doses of 0.5 mg/kg, 5 mg/kg, or 50 mg/kg was administered orally, once daily for 4 weeks. Kruskal–Wallis test followed by Mann–Whitney U test were used for statistical evaluation of loratadine effect in comparison with the control rats. ** P<0.01 in comparison with the control rats.

Abbreviations: C, control rats; Ca, calcium; L0.5, rats treated with loratadine at a dose of 0.5 mg/kg p.o.; L5, rats treated with loratadine at a dose of 5 mg/kg p.o.; L50, rats treated with loratadine at a dose of 50 mg/kg p.o.; P, phosphorus.